Atty Dkt No. 8600-0006 00-D0289

## COMBINED DECLARATION AND POWER OF ATTORNEY FOR UTILITY PATENT APPLICATION

AS A BELOW-NAMED INVENTOR, I HEREBY DECLARE THAT:
My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if more than one name is listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: NON-OVERLAPPING SPHERICAL THREE-DIMENSIONAL COIL the specification of which

X	is	at	tache	ed	hereto
	w	as	filed	lο	n

and assigned Serial No.

I HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE.

I acknowledge and understand that I am an individual who has a duty to disclose information which is material to the patentability of the claims of this application in accordance with Title 37, Code of Federal Regulations, §§ 1.56(a) and (b) which state:

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is canceled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is canceled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated

through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

- (1) prior art cited in search reports of a foreign patent office in a counterpart application, and
- (2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.
- (b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and
- (1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or
  - (2) It refutes, or is inconsistent with, a position the applicant takes in:
    - (i) Opposing an argument of unpatentability relied on by the Office,

or

(ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

I do not know and do not believe this invention was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to said application. This invention was not in public use or on sale in the United States of America more than one year prior to this application. This invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on any application filed by me or my legal representatives or assigns more than six months prior to this application.

I hereby claim priority benefits under Title 35, United States Code § 119(e)(1) of any United States provisional application(s) for patent as indicated below and have also identified below any application for patent on this invention having a filing date before that of the application for patent on which priority is claimed:

Application No.

Date of Filing
(day/month/year)

Priority
Claimed

Yes \_ No \_

I hereby appoint the following attorneys and agents to prosecute that application and to transact all business in the Patent and Trademark Office connected therewith and to file, to prosecute and to transact all business in connection with all patent applications directed to the invention:

Roberta L. Robins, Reg. No. 33,208 Dahna S. Pasternak, Reg. No. 41,411 Gary R. Fabian, Ph.D., Reg. No. 33,875 Cathleen M. Rocco, Rcg. No. 46,172 Luke Dohmen, Reg. No. 36,783 Peter J. Gafner, Reg. No. 36,517 Todd P. Messal, Reg. No. 42,883 Robert M. Rauker, Reg. No. 40,782 Albert K. Kau, Reg. No. 40,672

Address all correspondence to: Dahna S. Pasternak at

Customer No. 20855 **ROBINS & ASSOCIATES** 90 Middlefield Road, Suite 200 Menlo Park, CA 94025.

Address all telephone calls to: Dahna S. Pasternak at (650) 325-7812.

This appointment, including the right to delegate this appointment, shall also apply to the same extent to any proceedings established by the Patent Cooperation Treaty.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Signature: I'ull Name of Inventor: Clifford TEOH

Date 10-16-00

Citizenship: US

Residence: Los Altos, CA

Post Office Address: 1723 Juarez Avenue, Los Altos, CA 94024-6114

Signature:

Date 10-16-00

I'ull Name of Inventor: Michael P. WALLACE

Citizenship: US

Residence: Pleasanton, CA

Post Office Address: 3515 D Bernal Avenue, Pleasanton, CA 94566

## LIMITED AUTHORIZATION TO ACT ON BEHALF OF ASSIGNEE **REGARDING CERTAIN PATENT MATTERS** EFFECTIVE THROUGH: December 31, 2003

I, Paul W. Sandman, as Senior Vice President, Secretary, and General Counsel of Boston Scientific Corporation, the controlling corporation of:

AMS Medinvent S.A.; Boston Scientific BV; Boston Scientific Corporation Northwest Technology Center, Inc.; Boston Scientific Ireland Limited; Boston Scientific Japan KK; Boston Scientific Limited; Boston Scientific Scimed, Inc. (formerly known as Schneider (USA), Inc.); Cardiovascular Innovations Canada, Inc.; Corvita Canada, Inc.; Corvita Corporation; Corvita Europe S.A.; EP Technologies, Inc.; Laboratoires Corvita S.A.R.L.; Meadox Medicals, Inc.; NAMIC Eireann Limited; NAMIC International, Inc.; Nilo Holding, S.A.; Schneider (Europe) GmbH; Schneider Belgium NV; Schneider Holland BV; Schneider Ireland BV; Schneider Puerto Rico (formerly known as NAMIC Caribe, Inc.); Schneider/NAMIC; Scimed Life Systems, Inc.; Symbiosis Corporation; Target Therapeutics, Inc.; Cardiac Pathways Corporation; Interventional Technologies, Inc.; Embolic Protection, Inc.; Quanum Corporation; Smart Therapeutics, Inc.; Radio Therapeutics Corporation; Catheter Innovations Corp.; Enteric Medical Technologies, Inc.; BEI Medical Systems; Heart Technologies; Vesica; and Inflow Dynamics Inc.;

hereby authorize the following registered patent attorneys/agents (1) to act on behalf of any of the corporations identified above, including Boston Scientific Corporation, with regard to any matters before the United States Patent and Trademark Office, any foreign patent offices, and any international patent entities, (2) to execute power of attorney documents on behalf of any of the corporations identified above, including Boston Scientific Corporation, to appoint and/or establish any attorneys, agents, and/or law firms to act on behalf of any of the corporations identified above, including Boston Scientific Corporation, in any foreign or international patent applications filed with any foreign and/or international patent offices, and (3) to execute assignment and ownership documents on behalf of any of the corporations identified above, including Boston Scientific Corporation, with regard to any matters before the United States Patent and Trademark Office, any foreign patent offices, and any international patent offices:

Scott T. Bluni	Reg. No. 40,916
James R. Chiapetta	Reg. No. 39,634
Luke R. Dohmen	
Peter J. Gafner	•
Albert K. Kau	
Kurt W. Lockwood	<u> </u>
Steven A. McAuley	
Todd P. Messal	Reg. No. 42,883
Robert M. Rauker	_
William I. Shaw	<del>-</del>

Albei	't K. Kau	Keg. No. 40,672	
Kurt	W. Lockwood	Reg. No. 40,704	•
Steve	n A. McAuley	Reg. No. 46,084	
Todd	P. Messal	Reg. No. 42,883	
Robe	rt M. Rauker	Reg. No. 40,782	
	am J. Shaw	•	
<b>A</b> ( )	_		
Im Saw		4/11/03	
Paul W. Sandman		Date	
Senior Vice Presi <del>dent, S</del> ecre	tary, and General Counsel		
COMMONWEALTH OF MASSA			
COUNTY OF MIDDLESEX	) ss. )		
On this //th day of April the person described in and who and purposes set forth herein.	before me personal because the foregoing instrument, and	ally appeared Paul W. Sandman to me know I he duly acknowledged to me that he execu	n and known to me to be ted the same for the uses
5. 64/ 4	ong E. Hurd		
	TARY PUBLIC		[k:\Limited Authorizations(1)]

My commission expires Sept 18,2009